Oncologists now classify invasive breast cancer based on immunohistochemical analysis of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and proliferation factor Ki67, which not only provides prognostic information but it is also crucial for predicting treatment sensitivity. Here, ESR1 is linked to invasive breast carcinoma.